Valiant Lab Peer Comparison

NSE: VALIANTLAB | BSE: 543998

₹99.65

₹-5.24 (-5.00%)

As on 28-Aug-2026IST

Market cap

₹546 Cr

Revenue (TTM)

₹306 Cr

P/E Ratio

34.1

P/B Ratio

1.6

Div. Yield

0 %

Edit

	Valiant Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	546	35,497	29,798	16,589	15,507
Revenue (₹ Cr)	306	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	16.01	1,018.97	497.77	603.02	270.18
Net Margin (%)	5.19	10.47	20.72	22.63	23.29
RoE (%)	5.10	21.30	28.49	19.61	14.45
Price to Earnings	34.10	35.10	59.86	27.51	56.31
Price-To-Book	1.64	6.77	14.74	4.76	7.48

Income Statement (₹ Cr)

	Valiant Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	305.93	9,683.45	2,371.81	2,590.40	1,108.39
Total Income	308.45	9,730.84	2,402.61	2,664.23	1,159.90
Total Expenditure	272.67	7,739.53	1,608.91	1,753.71	720.01
EBITDA	33.26	1,943.92	762.90	836.69	388.38
Depreciation	8.37	425.10	98.11	78.88	74.78
EBIT	24.89	1,518.82	664.79	757.81	313.60
Interest	2.90	148.45	26.33	5.43	0.26
Other Income	2.53	47.39	30.80	73.83	51.50
Exceptional Items	0.00	-27.85	0.00	-25.66	-3.28
Profit before Tax	24.52	1,389.91	669.26	800.55	361.56
Provision for Tax	8.52	370.94	171.48	197.53	91.39
Profit after Tax	16.01	1,018.97	497.77	603.02	270.18

	Valiant Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	310.89	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	0.00	-7.58	0.00	0.00	2.51
Non-Current Liabilities	33.65	723.57	345.47	142.73	50.51
Current Liabilities	119.45	3,912.24	710.20	508.04	169.08
Total Liabilities	400.86	8,121.73	2,179.88	3,753.59	2,034.25

	Valiant Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	231.99	3,392.16	1,290.62	1,321.38	957.22
Current Assets	228.32	5,612.10	1,483.13	2,649.36	1,250.11
Total Assets	400.86	8,121.73	2,179.88	3,753.59	2,034.25
Total Debt*	121.20	731.70	136.01	0.00	0.38
Net Current Assets	108.88	1,699.86	772.93	2,141.33	1,081.04
Contingent Liabilities	61.89	393.94	8.97	4.82	3.91

	Valiant Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	1.31	851.71	317.40	391.52	244.52
Cash Flow from Investing Activities	-52.77	-94.00	-298.16	-615.65	-159.99
Cash from Financing Activities	44.65	-813.96	24.96	-6.23	-98.77
Net Cash Inflow / Outflow	-6.80	-56.25	44.21	-230.35	-14.24

	Valiant Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	-0.40	22.49	23.45	25.50	29.62
ROE (%)	5.10	21.30	28.49	19.61	14.45
ROA (%)	3.70	11.42	19.48	16.31	12.66
EBIT Margin (%)	8.14	15.68	28.03	29.25	28.29
Net Margin (%)	5.19	10.47	20.72	22.63	23.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Valiant Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	89.64	18.36	78.33	7.93	-6.72
EBIT Growth (%)	1,355.37	30.43	303.07	19.88	-26.64
Net Profit Growth (%)	12,503.15	32.39	182.61	21.66	-24.38
EPS Growth (%)	9,982.52	36.68	277.72	25.42	-21.99
Book Value Growth (%)	-1.08	50.94	18.89	20.94	18.74

	Valiant Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	34.10	34.38	59.86	26.64	55.82
Price / Book Value	1.64	6.77	14.74	4.76	7.48
Dividend Yield (%)	0.00	0.19	0.15	0.37	0.51
EV/EBITDA	17.77	18.80	38.85	18.89	38.86
Market Cap (₹ Cr)	333.66	20,327.45	15,494.53	13,228.83	17,537.35

	Valiant Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.09	0.05	0.09	0.00	0.00
Short term debt to equity ratio	0.07	0.11	--	--	0.00
Current Ratio	1.91	1.43	2.09	5.21	7.39
Quick Ratio	1.53	0.82	1.37	3.85	5.46
Interest Coverage	9.47	10.36	26.41	148.49	1,386.30

	Valiant Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	30.58	26.46	22.82	41.42	41.52
Asset Turnover	0.71	1.09	0.93	0.70	0.52
Receivable days	161.25	87.83	85.17	132.12	132.49
Inventory Days	19.16	78.64	90.97	102.08	68.07
Payable days	104.79	174.97	137.94	133.54	123.94
Cash Conversion Cycle	75.62	-8.50	38.21	100.66	76.63

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.